XOMA CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.03 USD | +1.54% |
|
+2.23% | +36.16% |
| 07:12pm | Xoma Changes Name to Xoma Royalty | MT |
| Jul. 01 | XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000 Growth Index | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
24.65
USD
Average target price
58
USD
Spread / Average Target
+135.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.86% | 287M | |
| +19.46% | 124B | |
| +19.94% | 114B | |
| +21.11% | 25.83B | |
| -23.73% | 19.42B | |
| -18.17% | 16.2B | |
| -20.50% | 15.31B | |
| +54.08% | 14.32B | |
| +8.13% | 14.31B | |
| -48.79% | 14.19B |
- Stock Market
- Equities
- XOMA Stock
- News XOMA Corporation
- Xoma Changes Name to Xoma Royalty
